prestwick fda approved chemical library  (Prestwick Chemical)

Journal: Cancer Biology & Therapy

Article Title: High-throughput screening identifies the activity of histone deacetylase inhibitors in patient-derived models of soft tissue sarcoma

doi: 10.1080/15384047.2025.2589666

Figure Lengend Snippet: Summary of Prestwick FDA approved chemical library and SCREEN-WELL PKE library screens. Cell cycle and cell number analysis for 4 UPS cell lines. (A) Phenotypic distance per cell line for each compound; DMSO (negative) and staurosporine (positive) were used as controls. The HDAC inhibitors CI-994, oxamflatin and trichostatin A are shown as exemplars. (B) Number of hit compounds in each cell line created with Venny 2.1 ( https://bioinfogp.cnb.csic.es/tools/venny/index.html ). (C) Table of IC 50 values for compounds taken forward for hit validation. IC 50 values were calculated from dose‒response curves of normalized nuclei counts following 72-h treatment. n = 4 data points per dose per cell line ( n = 2 biological repeats of technical duplicates).

Article Snippet: The Prestwick FDA Approved Chemical Library (1280 compounds; Prestwick Chemical) and SCREEN-WELL PKE library (176 compounds; Enzo Life Sciences) were tested in a single replicate at 10 μM on 4 UPS cell lines (SHEF_UPS01, SHEF_UPS02, SHEF_UPS03 and SHEF_UPS04).

Techniques: Biomarker Discovery

Journal: bioRxiv

Article Title: Phenotypic Screening Identifies Flunarizine as an Inhibitor of Radiotherapy-Induced Astrocyte Reactivity with Therapeutic Potential in Glioblastoma

doi: 10.1101/2025.07.12.664538

Figure Lengend Snippet: (A) Flowchart describing the workflow used to identify compounds that inhibit IR-induced astrocyte reactivity in primary human astrocytes. (B) Jitter plot showing the results of the primary screens, represented as distance scores to the non-IR control for two primary human astrocyte batches and three compound libraries. The dashed line indicates the hit threshold. (C) Pie charts showing the frequency of hits across the three libraries and the distribution of therapeutic classes among hits from the FDA-approved Prestwick Chemicals library. (D) Schematic illustrating the origin of compounds and the experimental strategy used for the confirmation screening. (E) Jitter plot of confirmation screen results represented as distance score to the non-IR control across four primary human astrocyte batches. The dashed line represents the hit threshold. (F) Summary of confirmed hits categorized by compound origin, clinical testing, blood–brain barrier (BBB) permeability, therapeutic class, and molecular targets. The final 12 prioritized compounds are listed.

Article Snippet: On the second day, cells were treated with one of the following libraries: 176 compounds from Enzo SCREEN-WELL Protease, Kinase and Epigenetics (PKE) Inhibitor libraries, 330 compounds from the TargetMol Anti-Cancer drugs library (#L2110, v2018) or 1,280 compounds from the FDA-approved Prestwick Chemical library (prestwickchemical.com, v2016).

Techniques: Control, Permeability